Abstract
ATP-binding cassette (ABC) transporter proteins, the most widely studied of which is P-glycoprotein (P-gp), function to translocate a wide range of xenobiotics across biological membranes, especially those exposed to the external environment. Radiopharmaceuticals that are substrates for ABC-transporter proteins are used to image their expression. They can be divided into single photon-emitters, especially technetium-99 m, and positron emitters, e.g. carbon-11 and fluorine-18. Tc-99m-MIBI has been most frequently used to image ABC transporters. Following passive diffusion into cytoplasm, it accumulates in mitochondria at a rate dependent on tissue perfusion and cellularity. Tissue retention of Tc-99m-MIBI correlates inversely with P-gp expression and can be modified with P-gp antagonists. Inter-individual variability of P-gp expression is linked to C3435T polymorphism of the human ABCB1 gene. C/C, T/C and T/T genotypes are associated with increased, intermediate and low P-gp expression, respectively. Functional up-regulation of ABC proteins results from exposure to inhibitors, resulting in acquired multi-drug resistance (MDR). Tc-99m-MIBI has been used for imaging MDR in several cancers. Early compounds developed to reverse MDR have not shown any benefit in patient outcome due to toxicity or interactions with chemotherapeutic agents. Newer MDR modulators, however, are less toxic, more specific for P-gp and do not interact with anti-cancer drugs. Combinations of chemotherapeutics to reverse MDR with tumour targeting agents are being evaluated. In conclusion, clinical trials optimally tailored to tumour types, genetic polymorphism and adequate dosing regimens need to be conducted and based on imaging for selecting patients whose cancers express MDR primarily though ABC-mediated mechanisms.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ABC-transporters:
-
ATP-binding cassette transporters
- MDR:
-
Multi drug resistance
- P-gp:
-
P-glycoprotein
- PET:
-
Positron emission tomography
- SPECT:
-
Single photon emission tomography
- MIBI:
-
Tc-99m-hexakis-methoxy-isobutyl isonitrile
References
Lockhart A, Tirona L, Kim R. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther. 2003;2:685–98.
Leslie E, Deeley R, Cole S. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005;1:216–37.
Aller S, Yu J, Ward A, et al. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science. 2009;323:1718–22.
Piwnica-Worms D, Chiu M, Budding M, Kronauge J, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 1993;53:977–84.
Sailaja K, Surekha D, Nageswara Rao D, et al. ABCB1 (MDR1, P-glycoprotein) C3435T gene polymorphism and its possible association with chronic myeloid leukemia prognosis. Curr Trends Biotechnol Pharm. 2008;2:514–22.
Kannan P, John C, Zoghbi S, et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther. 2009;86:368–77.
Szakács G, Paterson JK, Ludwig JA, et al. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34.
Mizutani T, Masuda M, Nakai E, et al. Genuine functions of P-glycoprotein (ABCB1). Curr Drug Metab. 2008;9:167–74.
Chaudhary P, Mechetner E, Roninson I. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 1992;11:2735–9.
Sharom F. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105–27.
Nagengast W, Oude Munnink T, Dijkers E, et al. Multidrug resistance in oncology and beyond: from imaging of drug efflux pumps to cellular drug targets. Methods Mol Biol. 2010;596:15–31.
Ballinger J. 99mTc-tetrofosmin for functional imaging of P-glycoprotein modulation in vivo. J Clin Pharmacol. 2001; 39S–47S.
Palestro CJ, Tomas MB, Tronco GG. Radionuclide imaging of the parathyroid glands. Semin Nucl Med. 2005;35:266–76.
Wale A, Miles K, Young B, et al. Combined 99mTc-methoxyisobutylisonitrile scintigraphy and fine-needle aspiration cytology offers an accurate and potentially cost-effective investigative strategy for the assessment of solitary or dominant thyroid nodules. Eur J Nucl Med Mol Imaging. 2014;41:105–15.
Chen Y, Wang W, Chan T, et al. A review of the cost-effectiveness of Tc-99m sestamibi scintimammography in diagnosis of breast cancer in Taiwanese women with indeterminate mammographically dense breast. Surg Oncol. 2002;11:151–5.
Ghibellini G, Vasist L, Heizer W, et al. Quantitation of Tc-99m-sestamibi bibliary exretion in humans. Clin Pharmacol Ther. 2005;79:19.
Piwnica-Worms D, Kronauge J, Chiu M. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells: mitochondrial and plasma membrane potential dependence. Circulation. 1990;82:1826–38.
Piwnica-Worms D, Kronauge J, LeFurgey A. Mitochondrial localization and characterization of 99Tc-SESTAMIBI in heart cells by electron probe X-ray microanalysis and 99Tc-NMR spectroscopy. Magn Reson Imaging. 1994;12:641–52.
Kabasakal L, Halac M, Nisli C. The effect of P-glycoprotein function inhibition with cyclosporine A on the biodistribution of Tc-99m-sestamibi. Clin Nucl Med. 2000;25:20–3.
Marian T, Balkay L, Szabo G. Biphasic accumulation kinetics of [99mTc]-hexakis-2-methoxyisobutyl isonitrile in tumour cells and its modulation by lipophilic P-glycoprotein ligands. Eur J Pharm Sci. 2005;25:201–9.
Ballinger J, Sheldon K, Boxen I. Differences between accumulation of 99mTc-MIBI and 201Tl-thallous chloride in tumour cells: role of P-glycoprotein. Q J Nucl Med. 1995;39: 122–8.
Joseph D, Bhargava K, Malhi H. Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes. Eur J Nucl Med Mol Imaging. 2003;30:1024–31.
Koomaji R, Stammler G, Manegold C, et al. Expression of resistance-related proteins in tumoral and peritumoral tissues of patients with lung cancer. Cancer Lett. 1996;110:129–36.
Chen C, Meadows B, Regis J, et al. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99 m sestamibi. Clin Cancer Res. 1997;3:545–52.
Luker G, Fracasso P, Dobkin J, et al. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo. J Nucl Med. 1997;38:369–72.
Casalta-Lopez J, Abrantes A, Rio J, et al. MDR and MDR reversal kinetics in humana adenocarcinoma cell lines. Eur J Nucl Med Mol Imaging. 2009;36:S242.
Vecchio S, Zannetti A, Salvatore B, et al. Functional imaging of multidrug resistance in breast cancer. Phys Med. 2006;21:24–7.
Schillaci O, Spanu A, Madeddu G. [99mTc]sestamibi and [99mTc]tetrofosmin in oncology: SPET and fusion imaging in lung cancer, malignant lymphomas and brain tumors. Q J Nucl Med Mol Imaging. 2005;49:133–44.
Muzi M, Mankoff D, Link J, et al. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J Nucl Med. 2009;50:1267–75.
Sharma V, Prior J, Belinsky M, et al. Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med. 2005;46:354–64.
Kurdziel KA, Kalen JD, Hirsch JI, et al. Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET-CT. J Nucl Med. 2011;52:1339–45.
Wanek T, Mairinger S, Langer O. Radioligands targeting P-glycoprotein and other drug efflux proteins at the blood-brain barrier. J Labelled Comp Radiopharm. 2013;56:68–77.
Bigott H, Prior J, Piwnica-Worms D, Welch M. Imaging multidrug resistance P-glycoprotein transport function using microPET with technetium-94m-sestamibi. Mol Imaging. 2005;4:30–9.
Mairinger S, Erker T, Müller M, et al. PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo. Curr Drug Metab. 2011;12:774–92.
Wong M, Evans S, Rivory L, et al. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther. 2005;77:33–42.
Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther. 2001;69:169–74.
Fromm M. Genetically determined differences in P-glycoprotein function: implications for disease risk. Toxicology. 2002;27:299–303.
Jamroziak K, Mlynarski W, Balcerczak E, et al. Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. Eur J Haematol. 2004;72:314–21.
Sigesmund M, Brinkmann U, Schaffeler E, et al. Association of the P-glycoprotein transporter MDR1C3435T polymorphism with the susceptibility to renal epithelial tumours. J Am Soc Nephrol. 2002;13:1847–54.
Seo T, Ishitsu T, Ueda N, et al. ABCB1 polymorphisms influence the response to antiepileptic drugs in Japanese epilepsy patients. Pharmacogenomics. 2006;7:551–61.
Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger U, et al. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet. 2001;358:383–4.
Shukla S, Wu C, Ambudkar S. Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol. 2008;4:205–23.
Koziolek M, Riess R, Geiger H, et al. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int. 2003;60:156–66.
Mohan H, Miles K. Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med. 2009;50:376–81.
Bleichner-Perez S, Le Jeune F, Dubois F, Steinling M. 99mTc-MIBI brain SPECT as an indicator of the chemotherapy response of recurrent, primary brain tumors. Nucl Med Commun. 2007;28:888–94.
Sasajima T, Shimada N, Naitoh Y, et al. (99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors. Int J Cancer. 2007;121:2637–45.
Kawata K, Kanai M, Sasada T, et al. Usefulness of 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer. Clin Cancer Res. 2004;10: 3788–93.
Mubashar M, Harrington K, Chaudhary K, et al. Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines. Acta Oncol. 2004;43:443–52.
Wang H, Chen X, Qiu F. Correlation of expression of multidrug resistance protein and messenger RNA with 99mTc-methoxyisobutyl isonitrile (MIBI) imaging in patients with hepatocellular carcinoma. World J Gastroenterol. 2004;109:1281–5.
Kostakoglu L. Noninvasive detection of multidrug resistance in patients with hematological malignancies: are we there yet? Clin Lymphoma. 2002;24:242–8.
Ciarmiello A, Del Vecchio S, Silvestro P, et al. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol. 1998;16:1677–83.
Mubashar M, Harrington K, Chaudhary K, et al. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. J Nucl Med. 2002;43:519–25.
Giovanella L, Suriano S, Maffioli M, et al. (99m)Tc-sestamibi scanning in thyroid nodules with nondiagnostic cytology. Head Neck. 2010;32:607–11.
Saggiorato E, Angusti T, Rosas R, et al. 99mTc-MIBI imaging in the presurgical characterization of thyroid follicular neoplasms: relationship to multidrug resistance protein expression. J Nucl Med. 2009;50:1785–93.
Pace L, Catalano L, Del Vecchio S, et al. Washout of [99mTc] sestamibi in predicting response to chemotherapy in patients with multiple myeloma. Q J Nucl Med Mol Imaging. 2005;49: 281–5.
Lee C. Reversing agents for ATP-binding cassette drug transporters. Methods Mol Biol. 2010;596:325–40.
Agrawal M, Abraham J, Balis FM, et al. Increased 99mTc-sestamibi accumulation in normal liver and drug-resistant tumors after the administration of the glycoprotein inhibitor, XR9576. Clin Cancer Res. 2003;9:650–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Dizdarevic, S., Peters, A.M. (2015). Radiopharmaceuticals for the Imaging of ABC-Transporter-Mediated Multidrug Resistance in Cancer. In: Efferth, T. (eds) Resistance to Targeted ABC Transporters in Cancer. Resistance to Targeted Anti-Cancer Therapeutics, vol 4. Springer, Cham. https://doi.org/10.1007/978-3-319-09801-2_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-09801-2_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-09800-5
Online ISBN: 978-3-319-09801-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)